Involvement of kallikrein‐PAR2‐proinflammatory pathway in severe trastuzumab‐induced cardiotoxicity

Trastuzumab‐induced cardiotoxicity interferes with continued treatment in approximately 10% of patients with ErbB2‐positive breast cancer, but its mechanism has not been fully elucidated. In this study, we recruited trastuzumab‐treated patients with ≥30% reduction in left ventricular ejection fracti...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Ritsuko, Kurebayashi, Nagomi, Eguchi, Hidetaka, Horimoto, Yoshiya, Shiga, Takahiro, Miyazaki, Sakiko, Kashiyama, Taku, Akamatsu, Wado, Saito, Mitsue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530879/
https://www.ncbi.nlm.nih.gov/pubmed/35879248
http://dx.doi.org/10.1111/cas.15508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530879/
https://www.ncbi.nlm.nih.gov/pubmed/35879248
http://dx.doi.org/10.1111/cas.15508

Ejemplares similares